MCRB SERES THERAPEUTICS INC Expansion Plans 8-K Filing 2025 - Financial Update Seres Therapeutics announced preliminary cash of $31 million as of December 31, 2024, and positive biomarker results from its SER-155 Phase 1b study, which may help reduce bloodstream infections in patients undergoing stem cell transplants.Get access to all SEC 8-K filings of the SERES THERAPEUTICS INC